Compare SNTI & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNTI | DARE |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 21.6M |
| IPO Year | 2021 | 2014 |
| Metric | SNTI | DARE |
|---|---|---|
| Price | $0.86 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $8.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 100.1K | 94.2K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | $7,627.27 | $3,195.79 |
| Revenue Next Year | N/A | $95.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $1.27 |
| 52 Week High | $5.10 | $9.19 |
| Indicator | SNTI | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 44.15 | 58.61 |
| Support Level | $0.80 | $1.67 |
| Resistance Level | $1.02 | $1.80 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 38.33 | 73.44 |
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.